Intra-Cellular Therapies (NASDAQ:ITCI) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Intra-Cellular Therapies (NASDAQ:ITCI) posted its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08), Zacks reports. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%.

Intra-Cellular Therapies Trading Up 0.1 %

Shares of Intra-Cellular Therapies stock traded up $0.07 during mid-day trading on Friday, reaching $128.61. 562,293 shares of the stock were exchanged, compared to its average volume of 4,171,555. The company has a market cap of $13.67 billion, a price-to-earnings ratio of -147.81 and a beta of 0.72. The firm has a 50-day simple moving average of $109.36 and a 200 day simple moving average of $89.29. Intra-Cellular Therapies has a fifty-two week low of $62.78 and a fifty-two week high of $128.77.

Insider Transactions at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Piper Sandler reissued a “neutral” rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their price objective for the company from $119.00 to $132.00 in a report on Friday, January 31st. Finally, Needham & Company LLC reissued a “hold” rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Nine analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $103.62.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.